Distinguishing between MS and neuromyelitis optica with optic neuritis


Physicians should hospitalize ON patients to prevent blindness, possible death.

Distinguishing between MS and neuromyelitis optica with optic neuritis

Reviewed by Robert C. Sergott, MD.

Recognizing that there is much that is new about an old disease is pivotal to the practice of comprehensive ophthal­mology, said Robert C. Sergott, MD, describing the new optic neuritis (ON) paradigm.

Sergott is director of the Neuro-Ophthalmology Service at Wills Eye Hospital and founding director and CEO of the Annesley EyeBrain Center at Thomas Jefferson University in Philadel­phia, Pennsylvania.

“Neuromyelitis optica [NMO] was a subject touched on briefly when I was in medical school and was extremely difficult to diagnose quickly,” he said. “Now it may be diagnosed easily and quickly because of a blood test for anti–aquaporin-4 antibodies. Every time this happens in medicine, what were thought previously to be rare diseases become more commonplace.”

The difference between multiple sclerosis (MS) and NMO with ON is that the prognosis of the lat­ter is much worse and can result in a stroke to the retina because of an immunologically mediated vas­culitis immunologic basis.

“Ophthalmologists must assume that every case of ON is NMO until the diagnostic study results are received,” he advised. Because of the risk of NMO with ON proceeding to ischemic damage in the retina, treatment with high-dose corticosteroids is time-sensitive.

Related: Fingolimod for MS offers disease control with no development of uveitis

Dissecting NMO

This immunologic disease was once thought to be rare, occurring with simultaneous bilateral ocular involvement and the presence of spinal cord symp­toms of myelopathy. However, the opposite is true, with the disease developing unilaterally and with or without spinal cord symptoms. Anti–myelin-associ­ated oligodendrocyte glycoprotein (anti-MOG) is a similar disorder that also must be recognized quickly.

Similar to ON and MS, NMO is far more common in women, and the incidence rates are 2 to 3 times higher in Black and Asian patients. Also, NMO is more active during and immediately after pregnancy. The median age of onset is 40 years, and the worse the visual loss, the more likely it is a diagnosis of NMO.

Gastrointestinal symptoms, including hiccups, weight loss, and itchiness, may help in the differ­ential diagnosis of NMO. However, the only current definitive tests are anti–aquaporin-4 and anti-MOG blood tests. Patients may have the classic findings of NMO but negative antibody titers, and they are now classified as seronegative NMO. Delays in the avail­ability of testing results necessitate the assumption that the patient has NMO until proven otherwise. “Treat first and establish the diagnosis afterward,” Sergott said. Not treating rapidly can result in an immunologically mediated ischemic optic neuropa­thy and/or central retinal artery occlusion.

Related: Infiltrative optic neuropathy in a patient with esophageal adenocarcinoma


A 29-year-old man with a 1-week history of right eyebrow pain, ocular pain, and pain with ocular movement reported decreased vision in his right eye with a visual acuity (VA) of 20/50; the VA in the fel­low eye was 20/20. The respective IOPs were 25 and 22 mm Hg. He started latanoprost bilaterally. With no improvement, he presented to the emergency department at Wills Eye Hospital. The patient’s his­tory was unremarkable. The VA was counting fin­gers and there was an afferent pupillary defect in the right eye. An MRI showed enhancement of the optic nerve in the right eye and an enlarged nerve in the left eye extending to the chiasm. No white matter lesions indicative of MS were seen.

“This long segment of an enhancing optic nerve lesion and a normal brain increases our clinical sus­picion for NMO , but it is not specific for the diag­nosis,” Sergott said.

What to do

An aggressive treatment approach is mandatory in NMO as is collaboration with other specialists. Oph­thalmologists are advised to quickly refer patients to the emergency department for neuroimaging of the optic nerves, brain, and spinal cord. There should be admission to the hospital, administration of in­travenous (IV) steroids, and collaboration with neu­rology or neuro-ophthalmology while awaiting the NMO titer results.

NMO has gone through a major therapeutic advance, Sergott pointed out. NMO is related to ophthalmology through the retinal blood vessels and those in and around the optic nerve. Research has indicated that B cells are stimulated to produce high concentrations of antibodies to aquaporin-4. Aquaporin 4 is highly localized to the astrocytic footplates that contact the retinal arterioles. The bottom line is that antibodies to aquaporin-4 are the pathogenesis of the periar­terial inflammation in NMO compared with MS in which the extravasation of immunologically active cells emerge in perivenular location. Complement activation and increased levels of IL-6 also develop.

Related: Analysis of 24-month data from the PALADIN study

He explained, based upon the elegant neuro-immunopathogenesis research of Claudia Lucchinetti, MD, of Mayo Clinic in Rochester, Minnesota, and others, that the current therapies are based on the following sequencing: first, IV methylpred­nisolone; second, plasmapheresis; and then either B-cell depletion, anti–IL-6 therapy, or complement inhibition.

Histopathologic studies have shown that NMO may produce ischemic damage, “strokes” in the spinal cord correlating very well with what can develop in the central retinal artery and its branches.

Natural history of NMO

In patients with spinal cord disease, 83% do poorly; in contrast, 67% of patients with ON do poorly. “This is much worse than the ON with MS,” Sergott said.

NMO attacks can result in blindness, paralysis, and death from neurogenic respiratory failure. Incom­plete recovery from attacks is the typical course that can result in cumulative disability. Within 5 years of NMO onset, more than 50% of patients are blind in 1 or both eyes or require ambulatory assistance, he noted.

Three medications have received FDA approval for treating NMO: Uplizna (inebilizumab-cdon, Viela Bio) for B-cell depletion; Soliris (eculizumab, Alex­ion Pharmaceuticals Inc.) for complement inhibition; and Enspryng (satralizumab, Chugai Pharmaceuti­cal) for anti–IL-6 activity. Sergott pointed out that ophthalmologists must recognize ON quickly and move in a different paradigm than before.

“It is no longer an option to wait to perform imag­ing,” he said. “All ON patients should be hospitalized. NMO and MS cannot be differentiated clinically, and NMO must be treated to prevent strokes in the optic nerve and retina.”

Related: Linking patient imaging data to AAO IRIS Registry

Specifically, Sergott advised treating with IV methylprednisolone upon admission to the hospi­tal, followed by MRI, a serologic work-up, and lum­bar puncture for NMO, Lyme disease, syphilis, and anti-MOG antibodies. If the vision does not improve with IV steroid treatment, plasmapheresis should be performed quickly. If unsuccessful, it should be fol­lowed by B-cell depletion, complement inhibition, or anti–IL-6 therapy.

A neuroradiologic clue to NMO involves the area postrema in the distal brainstem; when it is inflamed, hiccups, vomiting, and weight loss develop. Another clue is that the lesions in the spinal cord are lon­ger than in MS and can span 3 or more contiguous vertebral segments of the spinal cord and involve the central gray matter, with the lesions generally localized to the cervical and upper thoracic cord, Sergott said.

“In 2021, we have a new paradigm for ON. Oph­thalmologists should think NMO first and MS second. ON is NMO until proven otherwise to prevent strokes to the optic nerve and retina,” Sergott concluded.

e: rcs220@comcast.net
This article is adapted from Sergott’s presentation at the Ohio Ophthalmological Society’s 2021 virtual annual meeting. He has no financial disclosures related to this content.

Related Content: Imaging | Ophthalmology | Wet AMD Viewpoint | Retina in 2020

Related Videos
Retinal Inner Layer Disorganization and OCT in Uveitic Macular Edema: Insights from Dr. Amitha Domalpally
ARVO 2024: Study Reveals Faricimab's Potential for Extended Dosing in nAMD
TENAYA, LUCERNE year 2 data reveals promising results for faricimab
How to diagnose geographic atrophy earlier
World Sight Day 2022: Eye care professionals share what global vision means to them
Samsara Vision update: Concerto trial recruiting patients with late-stage AMD
Understanding fluid dynamics in wet macular degeneration
YOSEMITE, RHINE treat-and-extend data show favorable results for faricimab for the treatment of DME
What are you most excited about in the field of retina? Tunde Peto, MD, PhD weighs in
Leveraging noninvasive ophthalmic imaging for patients with Alzheimer disease and analyzing UK Biobank data
© 2024 MJH Life Sciences

All rights reserved.